Alterola Biotech, Inc.
ABTIOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$7443450
P/E Ratio—
52W High$0.2
52W Low$0.0002
Alterola Biotech, Inc.（ABTI）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ABTI · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2023-03 | 2022-03 | 2020-09 | 2019-09 | 2018-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Income Tax Expense | ($0.00B) | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.00 | $-0.01 | $-0.00 | $-0.00 | $-0.00 |
| Wtd Avg Shares | 0.81B | 0.77B | 0.12B | 0.12B | 0.12B |
| EBITDA | ($0.00B) | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · B
深入了解Alterola Biotech, Inc.
关于Alterola Biotech, Inc.（ABTI）损益表
Alterola Biotech, Inc.（ABTI）损益表数据来源于SEC Form 10-K及10-Q申报文件。2023财年，ABTI实现营收$0.00B，毛利润$0.00B（毛利率—），净利润($0.00B)（净利率—）。
常见问题
ABTI · 4 问Alterola Biotech, Inc.（ABTI）2023财年营收为$0.00B，同比down—%。
ABTI revenueABTI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09